Of note, Puente et al. reported IRF4 gene mutations among novel prognostic drivers in CLL, finding association with shorter time to first treatment, independently from clinical stage and immunoglobulin mutational status [63]. The gene discussed is IRF4; the disease is B-cell chronic lymphocytic leukemia.